胸腺肽α1辅助治疗老年COPD患者的临床疗效分析  

Analysis of clinical efficacy of thymosin α1 as the adjuvant therapy for elderly COPD patients

作　　者：何亦龙[1] 

机构地区：[1]广元市第二人民医院呼吸内科,四川广元628017

出　　处：《临床肺科杂志》2013年第12期2260-2261,共2页Journal of Clinical Pulmonary Medicine

摘　　要：目的探究胸腺肽α1辅助治疗老年COPD患者的临床疗效。方法对我院收治的150例老年COPD患者进行分组治疗,对比两组患者的临床疗效。结果两组患者治疗后FEV1、FVC及FEV1/FVC均显著上升,观察组上升程度更为明显;观察组总有效率90.7%,对照组为68.0%,观察组治疗效果明显优于对照组;两组患者治疗前后除CD8指标外,其余指标均明显上升,观察组上升程度更为明显;患者随访中未出现明显药物不良反应。结论胸腺肽α1能够有效调节老年COPD患者免疫水平,降低炎性反应,延缓病情进展。Objective To explore the effect of thymosin alpha 1 in the treatment of elderly patients with chronic obstructive pul- monary disease （COPD）. Methods 150 elderly patients with COPD in our hospital were randomly divided into two groups. The clinical effect was compared between the two groups. Results The levels of FEV1 , FVC and FEVJFVC increased significantly after the treat- ment in the two groups, and the improvement was more pronounced in the observation group than in the control group. The total effective rate was 90. 7% in the observation group and 68% in the control group. All indexes, except CD8, were better improved in the two groups after the treatment, and the improvement was more pronounced in the observation group than in the control group. There was no obvious adverse reaction occurred during follow-up. Conclusion Thymosin α 1 can effectively regulate the immune level in elderly patients with COPD, reduce the inflammatory response, and delay the progress of the disease.

关 键 词：胸腺肽Α1 慢性阻塞性肺疾病 老年 疗效 

分 类 号：R563.9[医药卫生—呼吸系统]